The company is selling the rights to a drug candidate aimed at rare blood and kidney disorders.

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

The addition of navtemadlin to ruxolitinib for JAK inhibitor-naive patients with myelofibrosis with suboptimal response to ...